Abstract
ObjectiveWhile a prognosis value of progesterone receptor (PR) in ovarian cancer has been reported in some publications, controversial data were presented by different reports. In order to address the disagreement of progesterone receptor in ovarian cancer survival, we conducted this meta-analysis.MethodsRelevant articles on progesterone receptor and ovarian cancer prognosis were identified via a thorough search of PubMed, Embase and Cochrane Central. Hazard ratios (HR) and 95% confidence interval (CI) were extracted from studies on overall survival (OS) and disease-free survival (DFS)/progress-free survival (PFS)/recurrence-free survival (RFS).ResultA total of 28 eligible studies containing 5685 patients were collected for analysis. It was found that progesterone receptor positivity was significantly associated with favorable overall survival (OS) (HR = 0.86, 95% CI = 0.78 to 0.95, P = 0.002) and disease-free survival (DFS)/progress-free survival (PFS)/recurrence-free survival (RFS) (HR = 0.75, 95% CI = 0.61 to 0.93, P = 0.008) of ovarian cancer patients. Subgroup analysis showed that progesterone receptor expression was associated with a favorable prognosis of unclassified ovarian cancer, European origin, and immunohistochemical detection method.ConclusionProgesterone receptor expression can be used as a favorable prognostic predictor in ovarian cancer managements.
Highlights
Ovarian cancer is the leading cause of death from gynecological malignancy and the fifth cause of death among women worldwide [1]
It was found that progesterone receptor positivity was significantly associated with favorable overall survival (OS) (HR = 0.86, 95% confidence interval (CI) = 0.78 to 0.95, P = 0.002) and disease-free survival (DFS)/progress-free survival (PFS)/recurrencefree survival (RFS) (HR = 0.75, 95% confidence interval (95% CI) = 0.61 to 0.93, P = 0.008) of ovarian cancer patients
Progesterone receptor expression can be used as a favorable prognostic predictor in ovarian cancer managements
Summary
Ovarian cancer is the leading cause of death from gynecological malignancy and the fifth cause of death among women worldwide [1]. In 2015, there were approximately 22,280 new cases and 14,240 deaths from ovarian cancer in the United States along [1]. This disease is often late-detected and progresses rapidly, has a poor prognosis [2, 3]. Over 70% of the patients are diagnosed at an advanced stage of disease, with a 5-year survival rate of merely 30% [4]. Despite modern management, such as cytoreductive surgery, and subsequent adjuvant chemotherapy, not all patients gain a benefit from these therapies [5, 6]. Discovery of applicable prognostic biomarkers for ovarian cancer is urgently required to improve the clinical outcomes of this disease
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
